Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study of PD-1 Inhibition With Pemrolizumab Alore or Combined With JAK 2 Inhibition in Myeloproliferative Neoplasm and Hodgkin's Lymphoma

NCT04016116 is registered in ClinicalTrials.gov with NYU Langone Health as lead sponsor.

NCT NCT04016116
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04016116 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study of PD-1 Inhibition With Pemrolizumab Alore or Combined With JAK 2 Inhibition in Myeloproliferative Neoplasm and Hodgkin's Lymphoma
Lead sponsor
NYU Langone Health
Phase
Phase 2
Overall status
Withdrawn
Start date
December 31, 2019
Completion date
December 31, 2021
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, hematological malignancy